Skip to main content

Heron Therapeutics, Inc.

HRTX
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0000818033

No open-market purchases or sales by Heron Therapeutics, Inc. insiders were filed in the last 90 days; 163 institutions reported holding it in 13F filings for Q2 2026, worth $57.1M in total; no superinvestor holds it.

Q3 2024 vs. Q2 2024

How the institutions holding Heron Therapeutics, Inc. changed between Q2 2024 and Q3 2024.

All holders in Q3 2024All holders in Q2 2024

13F holders of HRTX: Q2 2024 compared with Q3 2024
MeasureQ2 2024Of which not filed for Q3 2024Q3 2024Change
Holders1901173−16
Shares129.6M8.33M121.8M+520.7K (+0.4%)
Value$453.7M$29.1M$242.4M−$182.1M (−42.9%)

1 institution that held it in Q2 2024 haven't filed for Q3 2024 yet. Not filing isn't selling, so the changes leave them out.

New holders (22)

Institutions that held Heron Therapeutics, Inc. at the end of Q3 2024 but not at the end of Q2 2024.

Institutions new to HRTX in Q3 2024
InstitutionSharesValue% of portfolio
BlackRock, Inc.8,534,567$17.0M0.00%
HRT Financial LP426,817$849.0K0.00%
Anfield Capital Management, LLC112,712$224.3K0.09%
Intech Investment Management LLC35,988$71.6K0.00%
GWM Advisors LLC26,550$52.8K0.00%
Firethorn Wealth Partners, LLC26,013$51.8K0.03%
Bank of Montreal25,194$50.1K0.00%
Capstone Investment Advisors, LLC22,666$45.1K0.00%
Y-Intercept (Hong Kong) Ltd19,629$39.1K0.00%
Cutter & CO Brokerage, Inc.19,535$38.9K0.01%
EntryPoint Capital, LLC15,252$30.4K0.02%
Wolverine Trading, LLC11,465$22.8K0.00%
Moors & Cabot, Inc.10,750$21.4K0.00%
Cerity Partners LLC10,348$20.6K0.00%
Future Financial Wealth Managment LLC3,500$6.96K0.00%
Bessemer Group Inc1,425$3.00K0.00%
GeoWealth Management, LLC1,464$2.91K0.00%
Capital Performance Advisors LLP1,242$2.47K0.00%
True Wealth Design, LLC830$1.65K0.00%
Clear Street Markets LLC320$1.00K0.00%
Sterling Capital Management LLC349$6950.00%
Northwestern Mutual Wealth Management Co53$1050.00%

Sold out (38)

Institutions that held Heron Therapeutics, Inc. at the end of Q2 2024 and filed for Q3 2024 without it.

Not filed for Q3 2024 yet (1)

Institutions that held Heron Therapeutics, Inc. at the end of Q2 2024 and haven't filed a 13F for Q3 2024. Not filing isn't selling, so they aren't counted as sold out.

Institutions holding HRTX in Q2 2024 that haven't filed for Q3 2024
InstitutionShares, Q2 2024Value, Q2 2024
BlackRock Inc.8,325,385$29.1M